For Immediate Release
Interview with CAR T Cell Expert Dr. Michel Sadelain in Human Gene Therapy
Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com
New Rochelle, NY, May 18, 2018—Michel Sadelain, MD, PhD, Director, Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center in New York City, offers a fascinating perspective on the remarkable progress being made in the field of chimeric antigen receptor (CAR) engineered T-cell therapies to treat cancer. A lively and informative interview with Dr. Sadelain, in which he also describes his leading role in advancing this rapidly evolving field, is published in Human Genea peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free for download on the Human Gene Therapy website until June 18, 2018.
Jennifer Adair, PhD, Fred Hutchinson Cancer Research Center (Seattle, WA), conducted the interview with Dr. Sadelain, asking him to trace the stunning events that led to FDA approval of the first CAR T-cell therapy last summer to treat acute lymphoblastic leukemia (ALL). Dr. Sadelain recounts his early interest and ongoing research in CAR T-cell engineering and shares his views on what next-generation CAR technology will look like and what are the greatest challenges and opportunities for this promising field.
“Dr. Sadelain’s contributions have revolutionized the treatment of certain cancers,” says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. “While there have been earlier attempts to stimulate the immune system to battle cancerous cells, the CAR T technology has converted immune cells from being ‘dirty bombs’ to being ‘precision-guided weaponry’ in the fight against cancer, able to selectively target only the offending tumor cells.”
About the Journal
Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.